The packet lists no associated genes and no inheritance pattern for adenoid cystic carcinoma, so the genetic basis is not certified here. The definition notes that lymph node metastases are unusual and that hematogenous tumor spread, meaning spread through the bloodstream, is characteristic.

The packet does not certify specific diagnostic tests or criteria. The definition describes the microscopic appearance used to characterize the tumor: cribriform or classic, tubular, and solid basaloid patterns.

Treatment coverage is not certified in this packet, and no foundational therapies or FDA-approved treatments are recorded. Several investigational agents hold orphan drug designation for adenoid cystic carcinoma. Designation is a regulatory status and does not indicate approval, development stage, or availability.

The packet does not certify a natural history or outcome data for this condition. The definition states only that the tumor tends to recur and that spread through the bloodstream is characteristic.

According to ClinicalTrials.gov records in the packet, active clinical trials exist for this condition. They include early-phase and phase 2 studies, some focused on adenoid cystic carcinoma and others on salivary gland cancers more broadly, and the intervention types include drug therapy, biologic therapy, and procedural interventions such as radiotherapy. Active clinical trials for this condition are listed on ClinicalTrials.gov.